These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25601343)

  • 21. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment combinations for HER2-positive breast cancer.
    Pegram M
    Oncology (Williston Park); 2013 Apr; 27(4):258, 260. PubMed ID: 23781688
    [No Abstract]   [Full Text] [Related]  

  • 23. HER2 and response to paclitaxel in node-positive breast cancer.
    Mehta R
    N Engl J Med; 2008 Jan; 358(2):197-8; author reply 198. PubMed ID: 18193531
    [No Abstract]   [Full Text] [Related]  

  • 24. POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
    Goel S; Winer EP
    Oncology (Williston Park); 2015 Nov; 29(11):797-8, 802. PubMed ID: 26573058
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.
    Metzger-Filho O; Vora T; Awada A
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S31-9. PubMed ID: 20374028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.
    Azim HA; Rothé F; Aura CM; Bavington M; Maetens M; Rouas G; Gebhart G; Gamez C; Eidtmann H; Baselga J; Piccart-Gebhart M; Ellis C; Vuylsteke P; Cure H; Domont J; Ferro A; Toral-Peña JC; de Azambuja E; Sotiriou C; Di Cosimo S; Ignatiadis M
    Breast; 2013 Dec; 22(6):1060-5. PubMed ID: 24060577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].
    Mizuno Y; Chin K; Ando N; Oike E
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1293-6. PubMed ID: 16969027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of trastuzumab-refractory, HER2-positive metastatic breast cancer.
    Hurvitz S
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):260-2. PubMed ID: 25003356
    [No Abstract]   [Full Text] [Related]  

  • 29. Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.
    Sonke GS; Mandjes IA; Holtkamp MJ; Schot M; van Werkhoven E; Wesseling J; Vrancken Peeters MJ; Rodenhuis S; Linn SC
    Breast J; 2013; 19(4):419-26. PubMed ID: 23682812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pertuzumab (Perjeta) for preoperative use in HER2-positive breast cancer.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):98-9. PubMed ID: 24322664
    [No Abstract]   [Full Text] [Related]  

  • 31. Adjuvant chemotherapy for the treatment of HER2-positive early breast cancer.
    Clavarezza M; Venturini M
    Oncology; 2009; 77 Suppl 1():14-7. PubMed ID: 20130427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
    Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
    Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
    Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: bridging the gap between clinical trials and real life.
    Soares LR; Rosa VDL; Freitas-Junior R
    Breast Cancer Res Treat; 2020 Jun; 181(3):693-694. PubMed ID: 32350678
    [No Abstract]   [Full Text] [Related]  

  • 36. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?
    Gourmelon C; Frenel JS; Campone M
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):195-201. PubMed ID: 22316367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 39. [Update: adjuvant trastuzumab in HER2 positive breast cancer].
    Tahover E; Sonnenblick A; Peretz T; Katz D
    Harefuah; 2012 Jan; 151(1):37-42, 61. PubMed ID: 22670500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.